Welcome to our dedicated page for Aim Immunotech SEC filings (Ticker: AIMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Aim Immunotech's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Aim Immunotech's regulatory disclosures and financial reporting.
Aim ImmunoTech Inc. filed a notice that it will be late filing its Form 10-Q for the quarter ended September 30, 2025, citing delays in completing its review and the need for more time to compile and verify data. The company expects to file the report within the allowed extension period.
Preliminary figures for the three months ended September 30, 2025 show revenues of approximately $26,000, down from about $35,000 a year earlier, while net loss is expected to narrow to roughly $3,284,000 from about $3,700,000. For the nine-month period, revenue is expected to decrease to around $67,000 from about $125,000, with net loss improving to roughly $9,783,000 from about $11,353,000.
Net loss per share – basic and diluted – is expected to be about $(1.57) for the quarter versus $(6.00) a year earlier, and $(8.18) for the nine months versus $(21.00) in the prior-year period, indicating a smaller loss spread over the company’s share base.
AIM ImmunoTech Inc. launched an at-the-market offering of up to
The company notes non‑affiliate market value of approximately
AIM ImmunoTech Inc. reported that it filed its amended and restated Certificate of Incorporation as Exhibit 3.1(i). The updated certificate is consolidated through October 29, 2025 and supersedes prior exhibit pieces.
The filing lists exhibits under Item 9.01 and includes the Cover Page Inline XBRL file. AIM’s common stock trades on the NYSE American under the symbol AIM.
AIM ImmunoTech Inc. filed its definitive proxy for the 2025 Annual Meeting. The virtual meeting is set for December 16, 2025 at 11:00 a.m. Eastern Time. Stockholders of record at the close of business on October 24, 2025 may vote; shares outstanding and entitled to vote were 2,764,188 as of the record date.
The Board recommends voting FOR all five director nominees—Nancy K. Bryan, Thomas K. Equels, Ted D. Kellner, David I. Chemerow and William M. Mitchell—FOR ratification of BDO USA, P.C. as independent auditor for the fiscal year ending December 31, 2025, FOR approval, on an advisory basis, of named executive officer compensation, and selecting 1 YEAR for the frequency of future say‑on‑pay votes.
Directors will be elected by a plurality of votes cast; Proposals 2–4 require a majority in voting power of shares represented and entitled to vote. Quorum is 33 and 1/3% of shares entitled to vote. Proxies are being solicited by the Board; Sodali & Co. has been engaged to assist, for a fee of $20,000 plus expenses. AIM notes it is a smaller reporting company using scaled disclosures. Materials, including the 2024 Form 10‑K, are available via the company’s website and the SEC.
FAQ
What is the current stock price of Aim Immunotech (AIMI)?
What is the market cap of Aim Immunotech (AIMI)?
